Medical Advocates
ARV/HAART
  First Line ARV Regimens

 General Reports
Protease-Inhibitor-Based Therapies
NRTI-Based Therapies
NNRTI-Based Therapies
Drug-Specific Therapies

 


 
Drug-Regimens Main ARV-Naive Main Page Main New/Newsworthy Home Page      
Last Update:  December 22, 2005
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
   
     Journal Papers, Abstracts, and Commentaries
 
 
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy
(QUAD study).
Orkin C, Stebbing J, Nelson M, et al
J Antimicrob C J Antimicrob Chemother. 2004 Dec 17
 Abstract
 
Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study.
 Galli M, Cozzi-Lepri A, Ridolfo AL
 Arch Intern Med 2002 Dec 9-23;162(22):2621-8
 Abstract
 
Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in 
previously drug-naive individuals.
 Phillips AN, Miller V, Sabin C, et al.
AIDS 2001 Dec 7;15(18):2379-84
Abstract
 

Internet Reports
  FULL-TEXT REPORT
 ART Advances for Drug-Naive Patients: An Expert Interview With Calvin J. Cohen, MD
 C Cohen 
Medscape August 08, 2005
Protease Inhibitor-Based Therapies: General
   
     Journal Papers, Abstracts, and Commentaries
 
 

Secondary mutations in the protease region of human immunodeficiency virus
and virologic failure n drug-naive patients treated with protease inhibitor-based therapy.
Perno CF, Cozzi-Lepri A, Balotta C, et al.
J Infect Dis 2001 Oct 15;184(8):983-91
Abstract

  
NRTI-Based Therapies: General
   

     Journal Papers, Abstracts, and Commentaries

FULL-TEXT PDF ARTICLE
The Choice of the Nucleoside Backbone in Initial Therapy
 Gallant JE  
The Hopkins HIV Report, November 2004 Vol 16. No 6
 Paper

First-line therapy and mitochondrial damage: different nucleosides, different findings.
 Blanco F, Garcia-Benayas T, Jose De La Cruz J
 HIV Clin Trials 2003 Jan-Feb;4(1):11-99
 Abstract  

Simplification of antiretroviral treatment–how to sustain success, reduce toxicity and
ensure adherence avoiding PI use.
 Barreiro P, Garcia-Benayas T, Soriano V, Gallant J.
 AIDS Rev 2002 Oct-Dec;4(4):233-41
Abstract
 

A rational approach to the selection and sequencing of nucleoside/nucleotide analogues:
a new paradigm.
 Lange J.
 Antivir Ther 2001;6 Suppl 3:45-54
Abstract
NNRTI-Based Therapies: General
   

     Journal Papers, Abstracts, and Commentaries

  First-line therapy and mitochondrial damage: different nucleosides, different findings.
 Blanco F, Garcia-Benayas T, Jose De La Cruz J
 HIV Clin Trials 2003 Jan-Feb;4(1):11-99
 Abstract

Simplification of antiretroviral treatment–how to sustain success, reduce toxicity and
ensure adherence avoiding PI use.
 Barreiro P, Garcia-Benayas T, Soriano V, Gallant J.
 AIDS Rev 2002 Oct-Dec;4(4):233-41
 Abstract 		 

Drug-Regimens Main ARV-Naive Main Page Main New/Newsworthy Home Page      

 First-Line ARV-Specific Regimens